• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

验证 ICD-9-CM 代码在住院类风湿关节炎患者的行政索赔数据中识别胃肠道穿孔事件的有效性。

Validation of ICD-9-CM codes to identify gastrointestinal perforation events in administrative claims data among hospitalized rheumatoid arthritis patients.

机构信息

Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, FOT 805D, 510 20th Street South, Birmingham, AL 35294, USA.

出版信息

Pharmacoepidemiol Drug Saf. 2011 Nov;20(11):1150-8. doi: 10.1002/pds.2215. Epub 2011 Aug 27.

DOI:10.1002/pds.2215
PMID:22020901
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3227025/
Abstract

PURPOSE

To validate, using physician review of abstracted medical chart data as a gold standard, a claims-based algorithm developed to identify gastrointestinal (GI) perforation cases among rheumatoid arthritis (RA) patients.

METHODS

Patients with established RA, aged 18 years or older with hospital admissions between January 2004 and September 2009, were selected from a large US-hospital-based database. An algorithm with International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) diagnosis codes for GI perforation and combinations of GI-related diagnosis codes and Current Procedural Terminology (CPT-4) procedure codes for relevant GI surgeries was used to identify potential GI perforation cases. Two senior experienced specialist physicians independently reviewed abstracted chart data and classified cases as confirmed or unconfirmed GI perforations. Positive predictive values (PPVs) to identify confirmed GI perforation were calculated and stratified by upper versus lower GI tract.

RESULTS

Overall, 86 of 92 GI perforation cases were confirmed, yielding an overall PPV of 94% (95%confidence interval [CI] = 86%-98%). PPV was 100% (95%CI = 100%-100%) for upper GI perforation (esophagus, stomach) and 91% (95%CI = 90%-97%) for lower GI perforation (small intestine, PPV = 100%; large intestine, PPV = 94%; unspecified lower GI, PPV = 89%).

CONCLUSIONS

This algorithm, consisting of a combination of ICD-9-CM diagnosis and CPT-4 codes, could be used in future safety studies to evaluate GI perforation risk factors in RA patients.

摘要

目的

使用医生对病历数据摘要的审查作为金标准,验证一种旨在识别类风湿关节炎(RA)患者胃肠道(GI)穿孔病例的基于索赔的算法。

方法

从一个大型美国医院数据库中选择了年龄在 18 岁或以上、2004 年 1 月至 2009 年 9 月期间有住院记录的确诊 RA 患者。该算法使用了国际疾病分类,第九版,临床修订版(ICD-9-CM)GI 穿孔诊断代码和 GI 相关诊断代码与相关 GI 手术的当前程序术语(CPT-4)程序代码的组合,以识别潜在的 GI 穿孔病例。两名经验丰富的专家医生独立审查病历摘要数据,并将病例分类为确诊或未确诊的 GI 穿孔。计算了阳性预测值(PPV),以确定确诊的 GI 穿孔,并按上消化道与下消化道进行分层。

结果

总共 92 例 GI 穿孔病例中有 86 例得到确认,总体 PPV 为 94%(95%置信区间[CI] = 86%-98%)。上消化道(食管、胃)穿孔的 PPV 为 100%(95%CI = 100%-100%),下消化道(小肠、PPV = 100%;大肠,PPV = 94%;未指定的下消化道,PPV = 89%)的 PPV 为 91%(95%CI = 90%-97%)。

结论

该算法由 ICD-9-CM 诊断和 CPT-4 代码的组合组成,可在未来的安全性研究中用于评估 RA 患者的 GI 穿孔危险因素。

相似文献

1
Validation of ICD-9-CM codes to identify gastrointestinal perforation events in administrative claims data among hospitalized rheumatoid arthritis patients.验证 ICD-9-CM 代码在住院类风湿关节炎患者的行政索赔数据中识别胃肠道穿孔事件的有效性。
Pharmacoepidemiol Drug Saf. 2011 Nov;20(11):1150-8. doi: 10.1002/pds.2215. Epub 2011 Aug 27.
2
A systematic review of validated methods for identifying patients with rheumatoid arthritis using administrative or claims data.类风湿关节炎患者的行政或索赔数据识别方法的系统评价。
Vaccine. 2013 Dec 30;31 Suppl 10:K41-61. doi: 10.1016/j.vaccine.2013.03.075.
3
Identification of gastrointestinal perforation based on ICD-10 code in a Japanese administrative medical information database and associated drug exposure risk factors.基于日本行政医疗信息数据库中的国际疾病分类第十版(ICD-10)编码识别胃肠道穿孔及相关药物暴露风险因素。
Pharmacoepidemiol Drug Saf. 2019 Jul;28(7):976-984. doi: 10.1002/pds.4837. Epub 2019 Jun 13.
4
Chart validation of inpatient ICD-9-CM administrative diagnosis codes for acute myocardial infarction (AMI) among intravenous immune globulin (IGIV) users in the Sentinel Distributed Database.哨兵分布式数据库中静脉注射免疫球蛋白(IGIV)使用者急性心肌梗死(AMI)住院ICD-9-CM行政诊断代码的图表验证。
Pharmacoepidemiol Drug Saf. 2018 Apr;27(4):398-404. doi: 10.1002/pds.4398. Epub 2018 Feb 15.
5
Brief Report: Risk of Gastrointestinal Perforation Among Rheumatoid Arthritis Patients Receiving Tofacitinib, Tocilizumab, or Other Biologic Treatments.简要报告:接受托法替布、托珠单抗或其他生物制剂治疗的类风湿关节炎患者发生胃肠道穿孔的风险。
Arthritis Rheumatol. 2016 Nov;68(11):2612-2617. doi: 10.1002/art.39761.
6
A systematic review of validated methods for identifying systemic lupus erythematosus (SLE) using administrative or claims data.基于行政或索赔数据识别系统性红斑狼疮(SLE)的已验证方法的系统评价。
Vaccine. 2013 Dec 30;31 Suppl 10:K62-73. doi: 10.1016/j.vaccine.2013.06.104.
7
Validation of claims-based algorithms to identify interstitial lung disease in patients with rheumatoid arthritis.基于索赔的算法验证,以识别类风湿关节炎患者的间质性肺病。
Semin Arthritis Rheum. 2020 Aug;50(4):592-597. doi: 10.1016/j.semarthrit.2020.04.006. Epub 2020 May 20.
8
A systematic review of validated methods for identifying orthopedic implant removal and revision using administrative data.使用行政数据系统评价识别骨科植入物取出和翻修的验证方法。
Pharmacoepidemiol Drug Saf. 2012 Jan;21 Suppl 1:265-73. doi: 10.1002/pds.2309.
9
Factors associated with gastrointestinal perforation in a cohort of patients with rheumatoid arthritis.类风湿关节炎患者队列中与胃肠道穿孔相关的因素。
Arthritis Care Res (Hoboken). 2012 Dec;64(12):1819-28. doi: 10.1002/acr.21764.
10
Validation of anaphylaxis in the Food and Drug Administration's Mini-Sentinel.验证食品和药物管理局 Mini-Sentinel 中的过敏反应。
Pharmacoepidemiol Drug Saf. 2013 Nov;22(11):1205-13. doi: 10.1002/pds.3505. Epub 2013 Sep 5.

引用本文的文献

1
Comparison of the risk of gastrointestinal perforation between patients with and without rheumatoid arthritis: A nationwide cohort study in Asia.类风湿关节炎患者与非类风湿关节炎患者胃肠道穿孔风险的比较:一项亚洲全国性队列研究
Front Med (Lausanne). 2022 Sep 29;9:974328. doi: 10.3389/fmed.2022.974328. eCollection 2022.
2
Gastrointestinal perforations in patients with rheumatoid arthritis treated with biological disease-modifying antirheumatic drugs in Sweden: a nationwide cohort study.瑞典接受生物改善病情抗风湿药物治疗的类风湿关节炎患者的胃肠道穿孔:一项全国性队列研究。
RMD Open. 2020 Jul;6(2). doi: 10.1136/rmdopen-2020-001201.
3

本文引用的文献

1
The incidence of gastrointestinal perforations among rheumatoid arthritis patients.类风湿关节炎患者胃肠道穿孔的发生率。
Arthritis Rheum. 2011 Feb;63(2):346-51. doi: 10.1002/art.30107.
2
Adverse effects of non-steroidal anti-inflammatory drugs (NSAIDs, aspirin and coxibs) on upper gastrointestinal tract.非甾体抗炎药(NSAIDs,阿司匹林和 COX-2 抑制剂)对上消化道的不良影响。
Best Pract Res Clin Gastroenterol. 2010 Apr;24(2):121-32. doi: 10.1016/j.bpg.2009.11.005.
3
Validation of claims-based diagnostic and procedure codes for cardiovascular and gastrointestinal serious adverse events in a commercially-insured population.
An Integrated Analysis of the Safety of Tofacitinib in Psoriatic Arthritis across Phase III and Long-Term Extension Studies with Comparison to Real-World Observational Data.
托法替布治疗银屑病关节炎的 III 期临床研究和长期扩展研究的安全性综合分析,并与真实世界观察数据比较。
Drug Saf. 2020 Apr;43(4):379-392. doi: 10.1007/s40264-020-00904-9.
4
Characterizing Health Outcomes in Idiopathic Pulmonary Fibrosis using US Health Claims Data.利用美国健康索赔数据描述特发性肺纤维化的健康结局。
Respiration. 2020;99(2):108-118. doi: 10.1159/000504630. Epub 2020 Jan 24.
5
Characterizing idiopathic pulmonary fibrosis patients using US Medicare-advantage health plan claims data.利用美国医疗保险优势健康计划理赔数据对特发性肺纤维化患者进行特征描述。
BMC Pulm Med. 2019 Jan 10;19(1):11. doi: 10.1186/s12890-018-0759-5.
6
Gastrointestinal Perforations with Biologics in Patients with Rheumatoid Arthritis: Implications for Clinicians.类风湿关节炎患者使用生物制剂导致的胃肠道穿孔:对临床医生的启示。
Drug Saf. 2018 Jun;41(6):545-553. doi: 10.1007/s40264-018-0639-1.
7
Incidence of Gastrointestinal Perforations in Patients with Rheumatoid Arthritis Treated with Tocilizumab from Clinical Trial, Postmarketing, and Real-World Data Sources.从临床试验、上市后及真实世界数据来源分析接受托珠单抗治疗的类风湿关节炎患者胃肠道穿孔的发生率
Rheumatol Ther. 2016 Dec;3(2):337-352. doi: 10.1007/s40744-016-0037-z. Epub 2016 Jul 15.
8
Brief Report: Risk of Gastrointestinal Perforation Among Rheumatoid Arthritis Patients Receiving Tofacitinib, Tocilizumab, or Other Biologic Treatments.简要报告:接受托法替布、托珠单抗或其他生物制剂治疗的类风湿关节炎患者发生胃肠道穿孔的风险。
Arthritis Rheumatol. 2016 Nov;68(11):2612-2617. doi: 10.1002/art.39761.
9
Factors associated with gastrointestinal perforation in a cohort of patients with rheumatoid arthritis.类风湿关节炎患者队列中与胃肠道穿孔相关的因素。
Arthritis Care Res (Hoboken). 2012 Dec;64(12):1819-28. doi: 10.1002/acr.21764.
10
Derivation and preliminary validation of an administrative claims-based algorithm for the effectiveness of medications for rheumatoid arthritis.基于行政索赔的类风湿关节炎药物有效性算法的推导和初步验证。
Arthritis Res Ther. 2011;13(5):R155. doi: 10.1186/ar3471. Epub 2011 Sep 20.
基于索赔的心血管和胃肠道严重不良事件诊断和程序代码在商业保险人群中的验证。
Pharmacoepidemiol Drug Saf. 2010 Jun;19(6):596-603. doi: 10.1002/pds.1924.
4
Time trends and impact of upper and lower gastrointestinal bleeding and perforation in clinical practice.临床实践中上下消化道出血及穿孔的时间趋势和影响
Am J Gastroenterol. 2009 Jul;104(7):1633-41. doi: 10.1038/ajg.2009.164. Epub 2009 May 5.
5
IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial.用托珠单抗抑制白细胞介素-6受体可改善对抗肿瘤坏死因子生物制剂难治的类风湿关节炎患者的治疗效果:一项为期24周的多中心随机安慰剂对照试验的结果
Ann Rheum Dis. 2008 Nov;67(11):1516-23. doi: 10.1136/ard.2008.092932. Epub 2008 Jul 14.
6
Safety of long-term tacrolimus therapy for rheumatoid arthritis: an open-label, uncontrolled study in non-elderly patients.类风湿关节炎长期使用他克莫司治疗的安全性:一项针对非老年患者的开放标签、非对照研究。
Mod Rheumatol. 2008;18(4):345-53. doi: 10.1007/s10165-008-0058-8. Epub 2008 Apr 22.
7
Autoimmune disease concomitance among inflammatory bowel disease patients in the United States, 2001-2002.2001 - 2002年美国炎症性肠病患者中的自身免疫性疾病共患情况
Inflamm Bowel Dis. 2008 Jun;14(6):738-43. doi: 10.1002/ibd.20406.
8
TNF-mediated inflammatory disease.肿瘤坏死因子介导的炎症性疾病。
J Pathol. 2008 Jan;214(2):149-60. doi: 10.1002/path.2287.
9
Hyperhomocysteinemia, inflammation and autoimmunity.高同型半胱氨酸血症、炎症与自身免疫
Autoimmun Rev. 2007 Aug;6(7):503-9. doi: 10.1016/j.autrev.2007.03.008. Epub 2007 Apr 5.
10
Clustering of autoimmune diseases in families with a high-risk for multiple sclerosis: a descriptive study.多发性硬化症高危家庭中自身免疫性疾病的聚集性:一项描述性研究。
Lancet Neurol. 2006 Nov;5(11):924-31. doi: 10.1016/S1474-4422(06)70552-X.